Molecular Characterization of Mutations That Cause Globoid Cell Leukodystrophy and Pharmacological Rescue Using Small Molecule Chemical Chaperones
Open Access
- 21 April 2010
- journal article
- research article
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (16) , 5489-5497
Abstract
Globoid cell leukodystrophy (GLD) (Krabbe disease) is an autosomal recessive, degenerative, lysosomal storage disease caused by a severe loss of galactocerebrosidase (GALC) enzymatic activity. Of the >70 disease-causing mutations in theGALCgene, most are located outside of the catalytic domain of the enzyme. To determine howGALCmutations impair enzymatic activity, we investigated the impact of multiple disease-causing mutations on GALC processing, localization, and enzymatic activity. Studies in mammalian cells revealed dramatic decreases in GALC activity and a lack of appropriate protein processing into an N-terminal GALC fragment for each of the mutants examined. Consistent with this, we observed significantly less GALC localized to the lysosome and impairment in either the secretion or reuptake of mutant GALC. Notably, the D528N mutation was found to induce hyperglycosylation and protein misfolding. Reversal of these conditions resulted in an increase in proper processing and GALC activity, suggesting that glycosylation may play a critical role in the disease process in patients with this mutation. Recent studies have shown that enzyme inhibitors can sometimes “chaperone” misfolded polypeptides to their appropriate target organelle, bypassing the normal cellular quality control machinery and resulting in enhanced activity. To determine whether this may also work for GLD, we examined the effect of α-lobeline, an inhibitor of GALC, on D528N mutant cells. After treatment, GALC activity was significantly increased. This study suggests that mutations inGALCcan cause GLD by impairing protein processing and/or folding and that pharmacological chaperones may be potential therapeutic agents for patients carrying certain mutations.Keywords
This publication has 39 references indexed in Scilit:
- Psychosine Accumulates in Membrane Microdomains in the Brain of Krabbe Patients, Disrupting the Raft ArchitectureJournal of Neuroscience, 2009
- A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activityBiological Chemistry, 2007
- A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) regionHuman Mutation, 2007
- Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophyThe FASEB Journal, 2005
- A Common Temperature-sensitive Allelic Form of Human Tyrosinase Is Retained in the Endoplasmic Reticulum at the Nonpermissive TemperatureJournal of Biological Chemistry, 2000
- A Point Mutation Creating an ExtraN-Glycosylation Site in Fibrillin-1 Results in Neonatal Marfan SyndromeGenomics, 1996
- Krabbe Disease: Isolation and Characterization of a Full-Length cDNA for Human GalactocerebrosidaseBiochemical and Biophysical Research Communications, 1994
- Cloning and expression cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophyHuman Molecular Genetics, 1993
- Galactocerebrosidase from human urine: Purification and partial characterizationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- The twitcher mouse: degeneration of oligodendrocytes in vitroDevelopmental Brain Research, 1986